Fortis Group Advisors LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Fortis Group Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 100.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,972 shares of the biopharmaceutical company’s stock after purchasing an additional 3,486 shares during the quarter. Fortis Group Advisors LLC’s holdings in Pfizer were worth $201,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. GoalVest Advisory LLC lifted its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in Pfizer during the 4th quarter valued at $32,000. VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in Pfizer during the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Stock Performance

Shares of PFE stock traded down $0.12 on Friday, hitting $27.53. The company had a trading volume of 29,461,921 shares, compared to its average volume of 32,712,070. The firm has a market cap of $156.00 billion, a P/E ratio of -458.76, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The company has a 50-day moving average price of $27.56 and a 200-day moving average price of $27.78. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.36.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.10%. Pfizer’s payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.